Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Ralph Niven Sells 4,600 Shares

Aerovate Therapeutics, Inc. (NASDAQ:AVTEGet Free Report) insider Ralph Niven sold 4,600 shares of Aerovate Therapeutics stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $17.45, for a total value of $80,270.00. Following the transaction, the insider now owns 1,609 shares of the company’s stock, valued at $28,077.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ralph Niven also recently made the following trade(s):

  • On Friday, January 5th, Ralph Niven sold 4,600 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $19.16, for a total transaction of $88,136.00.
  • On Tuesday, December 5th, Ralph Niven sold 4,600 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $16.30, for a total transaction of $74,980.00.

Aerovate Therapeutics Stock Performance

AVTE stock opened at $20.53 on Friday. Aerovate Therapeutics, Inc. has a 52 week low of $9.41 and a 52 week high of $28.43. The company has a market capitalization of $568.07 million, a PE ratio of -7.47 and a beta of 1.12. The company’s 50-day simple moving average is $19.45 and its 200 day simple moving average is $15.80.

Aerovate Therapeutics (NASDAQ:AVTEGet Free Report) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01). On average, analysts forecast that Aerovate Therapeutics, Inc. will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Aerovate Therapeutics

A number of large investors have recently added to or reduced their stakes in AVTE. Vanguard Group Inc. lifted its position in Aerovate Therapeutics by 14.4% during the third quarter. Vanguard Group Inc. now owns 599,102 shares of the company’s stock worth $8,130,000 after purchasing an additional 75,535 shares during the period. Legal & General Group Plc lifted its holdings in shares of Aerovate Therapeutics by 33.2% during the 3rd quarter. Legal & General Group Plc now owns 7,692 shares of the company’s stock worth $104,000 after acquiring an additional 1,918 shares during the period. Alps Advisors Inc. boosted its position in shares of Aerovate Therapeutics by 11.3% during the 3rd quarter. Alps Advisors Inc. now owns 20,395 shares of the company’s stock worth $277,000 after acquiring an additional 2,075 shares in the last quarter. California State Teachers Retirement System increased its stake in Aerovate Therapeutics by 11.3% in the third quarter. California State Teachers Retirement System now owns 11,012 shares of the company’s stock valued at $149,000 after acquiring an additional 1,116 shares during the last quarter. Finally, Northern Trust Corp raised its position in Aerovate Therapeutics by 25.5% during the third quarter. Northern Trust Corp now owns 110,443 shares of the company’s stock valued at $1,499,000 after purchasing an additional 22,446 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently commented on AVTE. Wells Fargo & Company assumed coverage on shares of Aerovate Therapeutics in a report on Friday, December 8th. They set an “equal weight” rating and a $35.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Aerovate Therapeutics in a research report on Tuesday, November 14th.

Check Out Our Latest Report on AVTE

About Aerovate Therapeutics

(Get Free Report)

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

See Also

Insider Buying and Selling by Quarter for Aerovate Therapeutics (NASDAQ:AVTE)

Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.